Tunbekici, SalihSahin, GokhanOn, SercanOruc, AhmetEryilmaz, Melek KarakurtSakin, AbdullahCoskun, Alper2026-04-042026-04-0420260020-71361097-0215https://doi.org/10.1002/ijc.70213https://hdl.handle.net/11616/109979Sacituzumab govitecan (SG) is an antibody-drug conjugate approved for metastatic or unresectable locally advanced triple-negative breast cancer (mTNBC) after at least two prior systemic therapies, yet real-world evidence remains limited. We conducted a retrospective, multicenter study including 285 patients with unresectable locally advanced or metastatic TNBC treated with SG across 52 oncology centers in Turkey. Median progression-free and overall survival were 5.4 months (95% confidence interval [CI], 4.6-6.2) and 12.2 months (95% CI, 10.5-13.9), respectively, with a 12-month overall survival rate of 49.2%. The objective response rate and disease control rate in evaluable patients were 36.8% and 63.9%. Grades 3-4 adverse events, mainly neutropenia, occurred in 44.2% of patients. Dose reductions were needed in 20% of cases; no treatment-related deaths were reported. Our large real-world cohort reinforces the effectiveness and manageable safety profile of SG, mirroring pivotal trials, and highlights its value as a therapeutic option in diverse and heavily pretreated mTNBC populations.eninfo:eu-repo/semantics/closedAccessreal-world studysacituzumab govitecantriple-negative breast cancerArticle1587188118904114765510.1002/ijc.702132-s2.0-105020597792Q1WOS:001601304600001Q10000-0003-3060-377X0000-0003-0333-51910000-0002-9153-69210009-0009-6747-82640000-0003-1478-93830000-0001-6654-38150000-0001-9035-4846